Abstract
The incidence of melanoma in the United States continues to rise, with metastatic lesions notoriously recalcitrant to therapy. There are limited effective treatment options available and a great need for more effective therapies that can be rapidly integrated in the clinic. In this study, we demonstrate that the combination of RGD-Targeted adeno-Associated virus phage (RGD-AAVP-TNF) with hypofractionated radiation therapy results in synergistic inhibition of primary syngeneic B16 melanoma in a C57 mouse model. Furthermore, this combination appeared to modify the tumor microenvironment, resulting in decreased Tregs in the draining LN and increased tumor-Associated macrophages within the primary tumor. Finally, there appeared to be a reduction in metastatic potential and a prolongation of overall survival in the combined treatment group. These results indicate the use of targeted TNF gene therapy vector with radiation treatment could be a valuable treatment option for patients with metastatic melanoma.
Original language | English (US) |
---|---|
Pages (from-to) | 13-19 |
Number of pages | 7 |
Journal | Cancer gene therapy |
Volume | 24 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2017 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Cancer Research